The role of Ki67 proliferation assessment in predicting local control in bladder cancer patients treated by radical radiation therapy

Lara, Pedro C.; Rey, Agustín Sánchez; Santana, Carlos; Afonso, Juan L.; Díaz, Juan Sánchez; González, G; Apolinario, Rosa María Cáceres

doi:10.1016/s0167-8140(98)00033-4

Cited by 21 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In cystectomy-only series, a high proliferative index was consistently associated with an unfavorable clinical outcome (Table 6). After definitive radiotherapy, Lara et al found a significantly worse local control rate in bladder cancer patients with highly proliferating tumors [33]. Conversely, in the definitive radiotherapy series of Moonen et al and Osen et al no significant prognostic impact of Ki-67 on local control was noted [39,43].…”

Section: Discussionmentioning

confidence: 97%

Combined-Modality Treatment and Organ Preservation in Bladder Cancer

et al. 2005

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Combined-Modality Treatment and Organ Preservation in Bladder Cancer

et al. 2005

View full text Add to dashboard Cite

show abstract

“…In this series, there was a weak correlation between the Ki-67 index and local control. Other studies that have used Ki-67 as a marker of proliferation in transitional cell bladder cancer have reported a significantly lower progression-free and disease-specific survival rates in patients with higher Ki-67 indices (Popov et al, 1997;Lara et al, 1998;Moonen et al, 1998a;Rodel et al, 2000). Clinical data relating the effect of treatment duration on bladder outcome are equivocal (Maciejewski and Majewski, 1991;De Neve et al, 1995;Moonen et al, 1998b).…”

Section: P=00021mentioning

confidence: 99%

GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON

et al. 2003

View full text Add to dashboard Cite

Glucose transporter-1 protein (GLUT1) and carbonic anhydrase IX (CAIX) are regulated by hypoxia inducible factor-1 (HIF-1) and have been studied as putative intrinsic cellular markers for hypoxia. This study directly compares CAIX and GLUT1 with pimonidazole binding in a prospective series of bladder cancer patients and also studies the prognostic significance of the markers, in combination with vascularity and proliferation, in a retrospective series of bladder cancer patients treated in a phase II trial of radical radiotherapy with carbogen and nicotinamide (ARCON). A total of 21 patients with a diagnosis of transitional cell carcinoma of the bladder received 0.5 g m À2 pimonidazole. Serial tumour sections were stained for pimonidazole, GLUT1 and CAIX and compared. Tissue sections obtained from a series of 64 patients previously treated for invasive bladder cancer using ARCON were stained for GLUT1 and CAIX together with Ki-67 and CD31/34. There was a good geographical colocalisation of both intrinsic markers with pimonidazole and a highly significant agreement in individual patients; correlation coefficients were 0.82 (P ¼ 0.0001) for GLUT1 and 0.74 (Po0.0001) for CAIX. In both series of patients, the intrinsic hypoxia markers were highly correlated with each other and a correlation with proliferation was also evident in the retrospective study. In univariate and multivariate analyses, GLUT1 and CAIX were independent predictors for overall and cause specific survival. The hypoxia markers did not predict for local control or metastases-free survival although higher Ki-67 indices showed a trend towards local failure. The data suggest that both hypoxia modification and accelerated treatment may be valid treatment options in bladder cancer.

show abstract

“…15,21 The use of the median number of nuclei stained also has been suggested. 9,17,22,23 Currently, to our knowledge, there is no consensus about the ideal cut-off level for assessing p53 or MIB-1 immunohistochemical staining and outcome. We attempted to avoid this potential pitfall by examining p53 protein expression and MIB-1 as continuously scaled variables.…”

Section: P53 and Mib-1 In Tcc/frank Et Almentioning

confidence: 99%

Prognostic value of p53 and MIB‐1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement

Frank

Cheville

Blute

et al. 2004

Cancer

View full text Add to dashboard Cite

BACKGROUNDThe effect of p53 protein expression and MIB‐1 proliferative activity on survival and chemotherapeutic response in patients with lymph node (LN)‐positive transitional cell carcinoma (TCC) of the urinary bladder remains unclear. The objective of this study was to assess the ability of these markers to predict disease‐associated outcomes and response to chemotherapy in a cohort of patients with LN‐positive TCC.METHODSThe authors examined the expression of p53 and MIB‐1 in the LN metastases from 139 patients who underwent cystectomy for TCC at their institution. P53 and MIB‐1 nuclear staining were quantified using an image‐analysis system. Cox proportional hazards regression models were used to test associations of these markers with death from TCC, distant metastases, and local recurrence for all patients and in the subset of patients who were treated with adjuvant chemotherapy.RESULTSThe median p53 and MIB‐1 indices were 45.2% and 30.3%, respectively. The median follow‐up was 4.5 years (range, 0.1–10 years). There were no statistically significant associations noted between the p53 and MIB‐1 indices and the outcomes studied. When the analysis was limited to patients who were treated with adjuvant chemotherapy (n = 37 patients), the p53 index was found to have no prognostic value; however, there was a significant association between MIB‐1 and distant metastases (P = 0.049). When disease‐specific survival rates were stratified according to p53 index and chemotherapy, patients exhibited a response to chemotherapy regardless of p53 index.CONCLUSIONSp53 and MIB‐1 were not found to be associated significantly with disease‐related outcomes in patients with LN‐positive TCC. Adjuvant chemotherapy appeared to be effective regardless of p53 status. MIB‐1 may prove useful in predicting response to chemotherapy. Cancer 2004. © 2004 American Cancer Society.

show abstract

The role of Ki67 proliferation assessment in predicting local control in bladder cancer patients treated by radical radiation therapy

Cited by 21 publications

References 27 publications

Combined-Modality Treatment and Organ Preservation in Bladder Cancer

Combined-Modality Treatment and Organ Preservation in Bladder Cancer

GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON

Prognostic value of p53 and MIB‐1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement

Contact Info

Product

Resources

About